Page 221«..1020..220221222223..230240..»

Allergic to the world: can medicine help people with severe intolerance to chemicals? – The Guardian

Posted: September 25, 2022 at 2:04 am

Sharon calls herself a universal reactor. In the 1990s, she became allergic to the world, to the mould colonising her home and the paint coating her kitchen walls, but also deodorants, soaps and anything containing plastic. Public spaces rife with artificial fragrances were unbearable. Scented disinfectants and air fresheners in hospitals made visiting doctors torture. The pervasiveness of perfumes and colognes barred her from in-person social gatherings. Even stepping into her own back garden was complicated by the whiff of pesticides and her neighbours laundry detergent sailing through the air. When modern medicine failed to identify the cause of Sharons illness, exiting society felt like her only solution. She started asking her husband to strip and shower every time he came home. Grandchildren greeted her through a window. When we met for the first time, Sharon had been housebound for more than six years.

When I started medical school, the formaldehyde-based solutions used to embalm the cadavers in the human anatomy labs would cause my nose to burn and my eyes to well up representing the mild, mundane end of a chemical sensitivity spectrum. The other extreme of the spectrum is an environmental intolerance of unknown cause (referred to as idiopathic by doctors) or, as it is commonly known, multiple chemical sensitivity (MCS). An official definition of MCS does not exist because the condition is not recognised as a distinct medical entity by the World Health Organization or the American Medical Association, although it has been recognised as a disability in countries such as Germany and Canada.

Disagreement over the validity of the disease is partially due to the lack of a distinct set of signs and symptoms, or an accepted cause. When Sharon reacts, she experiences symptoms from seemingly every organ system, from brain fog to chest pain, diarrhoea, muscle aches, depression and odd rashes. There are many different triggers for MCS, sometimes extending beyond chemicals to food and even electromagnetic fields. Consistent physical findings and reproducible lab results have not been found and, as a result, people such as Sharon not only endure severe, chronic illness but also scrutiny over whether their condition is real.

The first reported case of MCS was published in the Journal of Laboratory and Clinical Medicine in 1952 by the American allergist Theron Randolph. Although he claimed to have previously encountered 40 cases, Randolph chose to focus on the story of one woman, 41-year-old Nora Barnes. She had arrived at Randolphs office at Northwestern University in Illinois with a diverse and bizarre array of symptoms. A former cosmetics salesperson, she represented an extreme case. She was always tired, her arms and legs were swollen, and headaches and intermittent blackouts ruined her ability to work. A doctor had previously diagnosed her with hypochondria, but Barnes was desperate for a real diagnosis.

Randolph noted that the drive into Chicago from Michigan had worsened her symptoms, which spontaneously resolved when she checked into her room on the 23rd floor of a hotel where, Randolph reasoned, she was far away from the noxious motor exhaust filling the streets. In fact, in his report Randolph listed 30 substances that Barnes reacted to when touched (nylon, nail polish), ingested (aspirin, food dye), inhaled (perfume, the burning of pine in fireplace) and injected (the synthetic opiate meperidine, and Benadryl).

He posited that Barnes and his 40 other patients were sensitive to petroleum products in ways that defied the classic clinical picture of allergies. That is, rather than an adverse immune response, such as hives or a rash where the body is reacting to a particular antigen, patients with chemical sensitivities were displaying an intolerance. Randolph theorised that, just as people who are lactose-intolerant experience abdominal pain, diarrhoea and gas because of undigested lactose creating excess fluid in their gastrointestinal tract, his patients were vulnerable to toxicity at relatively low concentrations of certain chemicals that they were unable to metabolise. He even suggested that chemical sensitivity research was being suppressed by the ubiquitous distribution of petroleum and wood products. MCS, he believed, was not only a matter of scientific exploration, but also of deep-seated corporate interest. Randolph concludes his report with his recommended treatment: avoidance of exposure.

In that one-page abstract, Randolph cut the ribbon on the completely novel but quickly controversial field of environmental medicine. Nowadays, we hardly question the ties between the environment and wellbeing. The danger of secondhand smoke, the realities of climate change and the endemic nature of respiratory maladies such as asthma are common knowledge. The issue was that Randolphs patients lacked abnormal test results (specifically, diagnostic levels of immunoglobulin E, a blood marker that is elevated during an immune response). Whatever afflicted them were not conventional allergies, so conventional allergists resisted Randolphs hypotheses.

Randolph was in the dark. Why was MCS only now rearing its head? He also asked another, more radical question: why did this seem to be a distinctly American phenomenon? After all, the only other mention of chemical sensitivities in medical literature was in the US neurologist George Miller Beards 1880 textbook A Practical Treatise on Nervous Exhaustion (Neurasthenia). Beard argued that sensitivity to foods containing alcohol or caffeine was associated with neurasthenia, a now-defunct term used to describe the exhaustion of the nervous system propagated by the USs frenetic culture of productivity. Like Beard, Randolph saw chemical sensitivities as a disease of modernity, and conceived the origin as wear-and-tear as opposed to overload.

Randolph proposed that Americans, propelled by the post-second world war boom, had encountered synthetic chemicals more and more in their workplaces and homes, at concentrations considered acceptable for most people. Chronic exposure to these subtoxic dosages, in conjunction with genetic predispositions, strained the body and made patients vulnerable. On the back of this theory, Randolph developed a new branch of medicine and, with colleagues, founded the Society for Clinical Ecology, now known as the American Academy of Environmental Medicine.

As his professional reputation teetered, his popularity soared and patients flocked to his care. Despite this growth in interest, researchers never identified blood markers in MCS patients, and trials found that people with MCS couldnt differentiate between triggers and placebos. By 2001, a review in the Journal of Internal Medicine found MCS virtually nonexistent outside western industrialised countries, despite the globalisation of chemical use, suggesting that the phenomenon was culturally bound.

MCS subsequently became a diagnosis of exclusion, a leftover label used after every other possibility was eliminated. The empirical uncertainty came to a head in 2021, when Quebecs public health agency, the INSPQ, published an 840-page report that reviewed more than 4,000 articles in the scientific literature, concluding that MCS is an anxiety disorder. In medicine, psychiatric disorders are not intrinsically inferior; serious mental illness is, after all, the product of neurological dysfunction. But the MCS patients I spoke to found the language offensive and irresponsible. Reducing what they felt in their eyes, throats, lungs and guts to anxiety was not acceptable at all.

As a woman I will call Judy told me: I would tell doctors my symptoms, and then theyd run a complete blood count and tell me I looked fine, that it must be stress, so theyd shove a prescription for an antidepressant in my face and tell me to come back in a year. In fact, because MCS is so stigmatising, such patients may never receive the level of specialised care they need. In the wake of her treatment, Judy was frequently bedbound from crushing fatigue, and no one took her MCS seriously. I think a lot of doctors fail to understand that we are intelligent, she said. A lot of us with chemical sensitivities spend a good amount of our time researching and reading scientific articles and papers. I probably spent more of my free time reading papers than most doctors.

Judy grew up in Texas, where she developed irritable bowel syndrome and was told by doctors that she was stressed. Her 20s were spent in Washington state where she worked as a consultant before a major health crash left her bedbound for years (again, the doctors said she was stressed). Later, after moving to Massachusetts, a new paint job at her home gave her fatigue and diarrhoea. She used to browse the local art museum every Saturday, but even fumes from the paintings irritated her symptoms. She visited every primary care doctor in her city, as well as gastroenterologists, cardiologists, neurologists, endocrinologists and even geneticists. Most of them reacted the same way: with a furrowed brow and an antidepressant prescription in hand. Not one allopathic doctor has ever been able to help me, Judy said.

Morton Teich is one of the few physicians who diagnoses and treats patients with MCS in New York. The entrance to his integrative medicine private practice is hidden away behind a side door in a grey-brick building on Park Avenue. As I entered the waiting room, the first thing to catch my eye was the monstrous mountain of folders and binders precariously hugging a wall, in lieu of an electronic medical record. I half-expected Teichs clinic to resemble the environmental isolation unit used by Randolph in the 1950s, with an airlocked entrance, blocked ventilation shafts and stainless-steel air-filtration devices, books and newspapers in sealed boxes, aluminium walls to prevent electromagnetic pollution, and water in glass bottles instead of a cooler. But there were none of the above. The clinic was like any other family medicine practice I had seen before; it was just very old. The physical examination rooms had brown linoleum floors and green metal chairs and tables. And there were no windows.

Although several of Teichs patients were chemically sensitive, MCS was rarely the central focus of visits. When he introduced me, as a student writing about MCS, to his first patient of the day, a petrol-intolerant woman whose appointment was over the phone because she was housebound, she admitted to never having heard of the condition. You have to remember, Teich told me, that MCS is a symptom. Its just one aspect of my patients problems. My goal is to get a good history and find the underlying cause. Later, when I asked him whether he had observed any patterns suggesting an organic cause of MCS, he responded: Mould. Almost always.

Many people with MCS I encountered online also cited mould as a probable cause. Sharon told me about her first episode in 1998, when she experienced chest pain after discovering black mould festering in her familys trailer home. A cardiac examination had produced no remarkable results, and Sharons primary care physician declared that she was having a panic attack related to the stress of a recent miscarriage. Sharon recognised that this contributed to her sudden health decline, but also found that her symptoms resolved only once she began sleeping away from home.

She found recognition in medical books such as Toxic (2016) by Neil Nathan, a retired family physician who argued that bodily sensitivities were the product of a hyper-reactive nervous system and a vigilant immune system that fired up in reaction to toxicities, much as Randolph had said. The conditions that Nathan describes are not supported by academic medicine as causes of MCS: mould toxicity and chronic Lyme disease are subject to the same critique.

Sharon went to see William Rea, a former surgeon (and Teichs best friend). Rea diagnosed her with MCS secondary to mould toxicity. Mould is everywhere, Teich told me. Not just indoors. Mould grows on leaves. Thats why people without seasonal allergies can become chemically sensitive during autumn. When trees shed their leaves, he told me, mould spores fly into the air. He suspected that American mould is not American at all, but an invasive species that rode wind currents over the Pacific from China. He mentioned in passing that his wife recently died from ovarian cancer. Her disease, he speculated, also had its roots in mould.

In fact, Teich commonly treats patients with nystatin, an antifungal medication used to treat candida yeast infections, which often infect the mouth, skin and vagina. I have an 80% success rate, he told me. I was dubious that such a cheap and commonplace drug was able to cure an illness as debilitating as MCS, but I could not sneer at his track record. Every patient I met while shadowing Teich was comfortably in recovery, with smiles and jokes, miles apart from the people I met in online support groups who seemed to be permanently in the throes of their illness.

However, Teich was not practising medicine as I was taught it. This was a man who believed that the recombinant MMR vaccine could trigger acute autism traditionally an anti-science point of view. When one of his patients, a charismatic bookworm Ill call Mark, arrived at an appointment with severe, purple swelling up to his knees and a clear case of stasis dermatitis (irritation of the skin caused by varicose veins), Teich reflexively blamed mould and wrote a prescription for nystatin instead of urging Mark to see a cardiologist. When I asked how a fungal infection in Marks toes could cause such a bad rash on his legs, he responded: We have candida everywhere, and its toxins are released into the blood and travel to every part of the body. The thing is, most people dont notice until its too late.

Moulds and fungi are easy scapegoats for inexplicable illnesses because they are so ubiquitous in our indoor and outdoor environments. A great deal of concern over mould toxicity (or, to use the technical term, mycotoxicosis) stems from the concept of sick-building syndrome, in which visible black mould is thought to increase sensitivity and make people ill. This was true of Mark, who could point to the demolition of an old building across the street from his apartment as a source of mould in the atmosphere. Yet in mainstream medicine, diseases caused by moulds are restricted to allergies, hypersensitivity pneumonitis (an immunologic reaction to an inhaled agent, usually organic, within the lungs) and infection. Disseminated fungal infections occur almost exclusively in patients who are immunocompromised, hospitalised or have an invasive foreign body such as a catheter. Furthermore, if clinical ecologists such as Teich are correct that moulds such as candida can damage multiple organs, then it must be spreading through the bloodstream. But I have yet to encounter a patient with MCS who reported fever or other symptoms of sepsis (the traumatic, whole-body reaction to infection) as part of their experience.

Teich himself did not use blood cultures to verify his claims of systemic candidiasis, and instead looked to chronic fungal infection of the nails, common in the general population, as sufficient proof.

I dont need tests or blood work, he told me. I rarely ever order them. I can see with my eyes that he has mould, and thats enough. It was Teichs common practice to ask his patients to remove their socks to reveal the inevitable ridges and splits on their big toenails, and thats all he needed.

Through Teich, I met a couple who were both chemically sensitive but otherwise just regular people. The wife, an upper-middle-class white woman I will call Cindy, had a long history of allergies and irritable bowel syndrome. She became ill whenever she smelled fumes or fragrances, especially laundry detergent and citrus or floral scents. Teich put both her and her husband on nystatin, and their sensitivities lessened dramatically.

What struck me as different about her case, compared with other patients with MCS, was that Cindy was also on a course of antidepressants and cognitive behavioural therapy, the standard treatment for anxiety and depression. It really helps to cope with all the stress that my illness causes. You learn to live despite everything, she said.

In contemporary academic medicine, stress and anxiety cause MCS, but MCS can itself cause psychiatric symptoms. Teich later told me, unexpectedly, that he had no illusions about whether MCS is a partly psychiatric illness: Stress affects the adrenals, and that makes MCS worse. The mind and the body are not separate. We have to treat the whole person.

Lose yourself in a great story: from politics to psychology, food to technology, culture to crime

To understand this case, I also spoke to Donald Black, associate chief of staff for mental health at the Iowa City Veterans Administration Health Care. He co-authored a recent article on idiopathic environmental intolerance that took a uniform stance on MCS as a psychosomatic disorder. In 1988, when Black was a new faculty member at the University of Iowa, he interviewed a patient entering a drug trial for obsessive-compulsive disorder. He asked the woman to list her medications, and watched as she started unloading strange supplements and a book about environmental illness from her bag.

The woman had been seeing a psychiatrist in Iowa City a colleague of Blacks who had diagnosed her with systemic candidiasis. Black was flummoxed. If that diagnosis was true, then the woman would be very ill, not sitting calmly before him. Besides, it was not up to a psychiatrist to treat a fungal infection. How did he make the diagnosis? Did he do a physical or run blood tests? No, the patient told him, the psychiatrist just said that her symptoms were compatible with candidiasis. These symptoms included chemical sensitivities. After advising the patient to discard her supplements and find a new psychiatrist, Black made some phone calls and discovered that, indeed, his colleague had fallen in with the clinical ecologists.

Black was intrigued by this amorphous condition that had garnered an endless number of names: environmentally induced illness, toxicant-induced loss of tolerance, chemical hypersensitivity disease, immune dysregulation syndrome, cerebral allergy, 20th-century disease, and mould toxicity. In 1990, he solicited the aid of a medical student to find 26 subjects who had been diagnosed by clinical ecologists with chemical sensitivities and to conduct an emotional profile. Every participant in their study filled out a battery of questions that determined whether they satisfied any of the criteria for psychiatric disorders. Compared with the controls, the chemically sensitive subjects had 6.3 times higher lifetime prevalence of major depression, and 6.8 times higher lifetime prevalence of panic disorder or agoraphobia; 17% of the cases met the criteria for somatisation disorder (an extreme focus on physical symptoms such as pain or fatigue that causes major emotional distress and problems functioning).

In my own review of the literature, it was clear that the most compelling evidence for MCS came from case studies of large-scale initiating events such as the Gulf war (where soldiers were uniquely exposed to pesticides and pyridostigmine bromide pills to protect against nerve agents) or the terrorist attacks on the US of 11 September 2001 (when toxins from the falling towers caused cancers and respiratory ailments for years). In both instances, a significant number of victims developed chemical intolerances compared with populations who were not exposed. From a national survey of veterans deployed in the Gulf war, researchers found that up to a third of respondents reported multi-symptom illnesses, including sensitivity to pesticides twice the rate of veterans who had not deployed. Given that Gulf war veterans experienced post-traumatic stress disorder at levels similar to those in other military conflicts, the findings have been used to breathe new life into Randolphs idea of postindustrial toxicities leading to intolerance. The same has been said of the first responders and the World Trade Centres nearby residents, who developed pulmonary symptoms when exposed to cigarette smoke, vehicle exhaust, cleaning solutions, perfume, or other airborne irritants after 9/11, according to a team at Mount Sinai.

Black, who doubts a real disease, has no current clinical experience with MCS patients. (Apart from the papers he wrote more than 20 years ago, he had seen only a handful of MCS patients over the course of his career.) Despite this, he had not only written the article about MCS, but also a guide in a major online medical manual on how to approach MCS treatment as a psychiatric disease. When I asked him if there was a way for physicians to regain the trust of patients who have been bruised by the medical system, he simply replied: No. For him, there would always be a subset of patients who are searching for answers or treatments that traditional medicine could not satisfy. Those were the people who saw clinical ecologists, or who left society altogether. In a time of limited resources, these were not the patients on which Black thought psychiatry needed to focus.

It became clear to me why even the de facto leading professional on MCS had hardly any experience actually treating MCS. In his 1990 paper, Black then a young doctor rightly observed that traditional medical practitioners are probably insensitive to patients with vague complaints, and need to develop new approaches to keep them within the medical fold. The study subjects clearly believed that their clinical ecologists had something to offer them that others did not: sympathy, recognition of pain and suffering, a physical explanation for their suffering, and active participation in medical care.

I wondered if Black had given up on these new approaches because few MCS patients wanted to see a psychiatrist in the first place.

Physicians on either side of the debate agreed that mental illness is a crucial part of treating MCS, with one I spoke to believing that stress causes MCS, and another believing that MCS causes stress. To reconcile the views, I interviewed another physician, Christine Oliver, a doctor of occupational medicine in Toronto, where she has served on the Ontario Task Force on Environmental Health. Oliver believes that both stances are probably valid and true. No matter what side youre on, she told me, theres a growing consensus that this is a public health problem.

Oliver represents a useful third position, one that takes the MCS illness experience seriously while sticking closely to medical science. As one of few MCS-agnostic physicians, she believes in a physiological cause for MCS that we cannot know and therefore cannot treat directly due to lack of research. Oliver agrees with Randolphs original suggestion of avoiding exposures, although she understands that this approach has resulted in traumatising changes in patients abilities to function. For her, the priority for MCS patients is a practical one: finding appropriate housing. Often unable to work and with a limited income, many of her patients occupy public housing or multi-family dwellings. The physician of an MCS patient must act like a social worker. Facilities such as hospitals, she feels, should be made more accessible by reducing scented cleaning products and soaps. Ultimately, finding a non-threatening space with digital access to healthcare providers and social support is the best way to allow the illness to run its course.

Whether organic or psychosomatic or something in between, MCS is a chronic illness. One of the hardest things about being chronically ill, wrote the American author Meghan ORourke in the New Yorker in 2013 about her battle against Lyme disease, is that most people find what youre going through incomprehensible if they believe you are going through it. In your loneliness, your preoccupation with an enduring new reality, you want to be understood in a way that you cant be.

A language for chronic illness does not exist beyond symptomatology, because in the end symptoms are what debilitate normal human functioning. In chronic pain, analgesics can at least deaden a patients suffering. The same cannot be said for MCS symptoms, which are disorienting in their chaotic variety, inescapability and inexpressibility. There are few established avenues for patients to completely avoid triggering their MCS, and so they learn to orient their lives around mitigating symptoms instead, whether that is a change in diet or moving house, as Sharon did. MCS comes to define their existence.

As a housebound person, Sharons ability to build a different life was limited. Outside, the world was moving forward, yet Sharon never felt left behind. What allowed her to live with chronic illness was not medicine or therapy, but the internet. On a typical day, Sharon wakes up and prays in bed. She wolfs down handfuls of pills and listens to upbeat music on YouTube while preparing her meals for the day: blended meats and vegetables, for easier swallowing. The rest of the day is spent on her laptop computer, checking email and Facebook, watching YouTube videos until her husband returns home in the evening. Then bed. This is how Sharon has lived for the past six years, and she does not expect anything different from the future. When I asked her if being homebound was lonely, I was taken aback at her reply: No.

In spite of not having met most of her 15 grandchildren (with two more on the way), Sharon keeps in daily contact with all of them. In fact, Sharon communicates with others on a nearly constant basis. Some people are very much extroverts, Sharon wrote. I certainly am. But there are also people who need physical touch and I can understand why they might need to see real people then but its very possible to be content with online friends. This is my life! The friendships that Sharon formed online with other housebound people with chronic illnesses were the longest-lasting and the most alive relationships she had ever known. She had never met her best friend of 20 years their relationship existed completely through letters and emails, until two years ago, when the friend died. That was very hard for me, Sharon wrote.

The pandemic changed very little of Sharons life. If anything, Covid-19 improved her situation. Sharons local church live-streamed Sunday service, telehealth doctor appointments became the default, YouTube exploded in content, and staying indoors was normalised. Sharon saw her network steadily expand as more older adults became isolated in quarantine.

People within the online MCS community call themselves canaries, after the birds historically used as sentinels in coalmines to detect toxic levels of carbon monoxide. With a higher metabolism and respiratory rate, the small birds would theoretically perish before the less-sensitive human miners, providing a signal to escape. The question for people with MCS is: will anyone listen?

Us canaries, said a woman named Vera, who was bedbound from MCS for 15 years after a botched orthopaedic surgery, we struggle and suffer in silence. Now, in the information age, they have colonised the internet to find people like themselves. For our part, we must reimagine chronic illness which will become drastically more common in the aftermath of the pandemic where what matters to the patient is not only a scientific explanation and a cure, but also a way to continue living a meaningful life. This calls into action the distinction between illness and disease that the psychiatrist and anthropologist Arthur Kleinman made in his 1988 book The Illness Narratives. Whereas a disease is an organic process within the body, illness is the lived experience of bodily processes. Illness problems, he writes, are the principal difficulties that symptoms and disability create in our lives.

By centring conversations about MCS on whether or not it is real, we alienate the people whose illnesses have deteriorated their ability to function at home and in the world. After all, the fundamental mistrust does not lie in the patient-physician relationship, but between patients and their bodies. Chronic illness is a corporeal betrayal, an all-out assault on the coherent self. Academic medicine cannot yet shed light on the physiological mechanisms that would explain MCS. But practitioners and the rest of society must still meet patients with empathy and acceptance, making space for their narratives, their lives, and their experience in the medical and wider world.

This essay was originally published in Aeon

Follow the Long Read on Twitter at @gdnlongread, listen to our podcasts here and sign up to the long read weekly email here.

View post:
Allergic to the world: can medicine help people with severe intolerance to chemicals? - The Guardian

Posted in Integrative Medicine | Comments Off on Allergic to the world: can medicine help people with severe intolerance to chemicals? – The Guardian

Do Well, Be Well with Diabetes program starts Oct. 6 in Waco – AgriLife Today

Posted: September 25, 2022 at 2:02 am

TheTexas A&M AgriLife Extension Serviceoffice inMcLennan Countywill present a free Do Well, Be Well with Diabetes program beginning on Oct. 6 in Waco.

The five-week program is for people with Type 2 diabetes. It will be held from 5:30-7:30 p.m. on Thursdays through Nov. 3 at the AgriLife Extension office in McLennan County at 4224 Cobbs Drive.

There is no cost to attend, but preregistration is required by calling the AgriLife Extension office at 254-757-5180.

The program will be taught by Colleen Foleen, AgriLife Extension family and community health agent, and Ashley Cox, AgriLife Extension family and community assistant agent, both serving McLennan County.

We will explore a new topic each week, and this is also a good opportunity to get the encouragement to make positive changes and meet others who have the same concerns about diabetes as you, Cox said.

For additional information or questions, contact Foleen at colleen.foleen@ag.tamu.edu or Cox at ashley.cox@ag.tamu.edu.

The Do Well, Be Well with Diabetes program will provide participants with:

-30-

Read the original:
Do Well, Be Well with Diabetes program starts Oct. 6 in Waco - AgriLife Today

Posted in Diabetes | Comments Off on Do Well, Be Well with Diabetes program starts Oct. 6 in Waco – AgriLife Today

Prevalence and predictors of diabetes-related distress in adults with type 1 diabetes | Scientific Reports – Nature.com

Posted: September 25, 2022 at 2:02 am

We found that more than one-third of our study sample suffered from substantial diabetes-related distress. Previous studies showed that elevated diabetes-related distress affects 2030% of people with T1DM, with the range difference recorded in prevalence across different populations and healthcare systems from 8 to 65%5. Our results are concordant with the study in the USA which reported prevalence of diabetes-related distress in T1DM of 42.1%20. The same study showed that, among those with elevated diabetes-related distress at baseline, 71% report similarly high levels at nine month follow-up. Interestingly, we found that the duration of the disease did not predict diabetes-related distress. Several explanations are possible. For example, the source of distress could have changed over time, as in the example where duration is strongly associated with both complications and hypoglycemia risk. Alternatively, it may indicate that adaptation to distress in persons with T1DM is not a matter of time, as a passive process, but that it requires the person to actively cope with the illness and accept the changes in life that are associated with the occurrence of DM. For example, to accept their own fears of the complications instead of denying it and not adhering to the diet, new healthy lifestyle etc. This may indirectly indicate that a psychosocial intervention may be needed to help the person cope with diabetes-related distress. This may be especially important for those with prolonged distress, as it can predispose to problematic self-care behavior7. Indeed, severe diabetes-related distress increases the chances of poor treatment outcomes and the risk of diabetes-related complications21. Of course, other factors such as general coping abilities and life circumstances (for example poor socioeconomic status) not assessed in this study that relate to diabetes distress may explain these results.

The mean PAID total score in our study was 31.92 (21.14)and is comparable to the results of SAGE study22.

The results of our study indicate that the presence of elevated HbA1c levels is a significant predictor of diabetes distress. This is concordant with the results of the T1 Exchange Clinic Registry in which HbA1c was one of the strongest predictors significantly associated with diabetes-related stress when adjusting for all other variables15.

It is possible that uncontrolled diabetes, defined by high HbA1c levels, elevates the distress in patients, as patients may be worried about the consequences of diabetes and the lack of success in the treatment, especially over a course of time. However, it is also possible that other features, such as anxiety or overwhelming distress in life, may confer to both the increase of stress related to diabetes and to elevated levels of HbA1c.

Concordant with our finding which indicates that the presence of elevated HbA1c levels is a significant predictor for diabetes distress, we also found that the presence of microvascular complications is also a significant predictor. First, we may assume that those with higher levels of HbA1c will also have a higher probability to develop microvascular complications23, indicating that (psychological) factors contributing to elevated HbA1c may result in contributing to microvascular complications over time. Secondly, it is also possible that acquiring microvascular complications lead to impairment of organ functioning that the patient feels through loss or impaired functioning or limitation in everyday life, and thus the fear of disease and potential impact on ability in the future as well distress increase. No other significant predictors for higher diabetes-related distress among sociodemographic and disease characteristics were found. While associations between diabetes-related distress and gender, decreased age, and diabetes duration were demonstrated elsewhere15, our study findings yield no difference in the level of diabetes-related distress among genders and age groups. A possible explanation could be the higher mean age of our study sample which was 48.11 (15.53) vs 37.64 (16.33) in T1 Exchange Clinic Registry. The second possibility is the different method of calculation, which in our study was binary logistic regression with the main variable being categorized as either above cut-off score or below, while the mentioned study used the original continuous PAID score variable. Interestingly, most of our study participants were worried about complications, (e.g., neuropathy, retinopathy, and nephropathy) and hypoglycemia, which are described as the most prevalent diabetes-specific fears in people with diabetes24, so intervention in patient education is justified.

In our study we found that some individual items in the PAID questionnaire were highly scored by majority of studied population, pointing to moderate or severe distress regarding a particular topic25. Worrying about the future and chronic complications and feeling guilty when off-track with diabetes management were the most prominent concerns, and these findings are comparable with the results of a previous study of diabetes-related distress made in Croatian population with both type 1 and type 2 diabetes participants26. Interestingly, feeling guilty when off-track with management was the most prominent description of feelings associated with distress, followed by feeling burnt-out by the constant effort needed to manage diabetes and feeling scared and depressed when thinking about living with diabetes, coping with complications and blood sugar levels, which may indicate the formation of the vicious cycle in which the patients with DM are caught in, by trying and failing to control their illness and future of it27. For example, their constant worrying about the complication of diabetes due to non-optimal glycemia levels and the negative predictions about the future of their illness increasing their level of fear/anxiety may result in the patients feeling burnt by the constant effort needed to manage diabetes (to control their illness glycemia levels) leading to increased depression and fear due to living with diabetes, which then increases the negative perceptions of the future forming the vicious cycle28. Alternatively, constant worrying about the complications and negative predictions about the future of their illness, fear and depression may also lead to denial of the potential effects of chronic diabetes mellitus, which results in them failing to adhere to diet/medication and leading to non-optimal glycemia and ultimately increasing the possibility of complications of DM, followed by feelings of guilt when off-track with diabetes management29. This will again increase their worrying about complications closing the vicious cycle. The way how diabetes-related distress manifests in the two different populations may be contextually different due to differences in age, predisposing conditions, treatment outcomes, and type of treatment. Our findings on commonly perceived distress items solely in T1DM population could be a signal to the clinicians on what to address in clinical consultation.

The importance of psychosocial care and a call for improved psychosocial outcomes are recognized by the American Diabetes Association which issued recommendations to integrate psychosocial care within patient-centered medical care, stressing that such care should be provided to all diabetic patients30. Furthermore, the recent Consensus Report on the management of T1DM acknowledged ongoing psychosocial support as a relevant component of T1DM management, as treatment outcomes are highly dependent on a persons ongoing self-care behavior9. Notably, our findings suggest that social support availability is perceived as highly relevant by our study participants as more than 80% of participants reported scores<3 to the associated item 18. Thus, psychosocial support could be a protective factor from diabetes related distress and perceived problems with self-management in adults with diabetes31. Screening and monitoring for psychosocial problems using patient-appropriate standardized and validated tools are recommended at the initial visit, and periodically thereafter if glycemic targets are not met and/or at the onset of diabetes complications. While the treatment of psychological aspects related to T1DM may be as important as the medical management in improving living with diabetes32, the method of delivering it is still unclear33.

The screening should be used to detect the overall levels of diabetes-related distress, at the very beginning of the treatment. Depending on the PAID scores, several interventions should be offered, in addition to the standard treatment, including education. For those with low to moderate levels of diabetes-related distress, education should be provided in an empathic form by the health care team treating diabetes, seeing as 67% of participants expressed satisfaction with their diabetes physician. For highly distressed adults with T1DM, having poor glycemic control, diabetes-related distress can be successfully addressed using both educational and emotion-focused approaches34. In addition, psychological or psychiatric liaison consultations should be available.

Considerable strengths of the study are the inclusion of a representative sample of T1DM patients treated at secondary and tertiary centers in Croatia and the usage of standardized, diabetes-specific measure that allows for replication of the study findings. Our results made solely in T1DM patients give greater clarity of understanding this condition in specific patients. Lastly, according to our knowledge, this is the first study of this kind in Croatia.

Limitations of this study include a cross-sectional design which implies interpretation and clinical recommendations should be made with caution. The sample size is likely too small to confirm the lack of association among many of the variables. Other comorbidities or life events that could influence distress levels were not assessed and evaluated in this study.

Go here to read the rest:
Prevalence and predictors of diabetes-related distress in adults with type 1 diabetes | Scientific Reports - Nature.com

Posted in Diabetes | Comments Off on Prevalence and predictors of diabetes-related distress in adults with type 1 diabetes | Scientific Reports – Nature.com

Navratri fasting tips 2022: Dos and don’ts for people with diabetes during fasts – Hindustan Times

Posted: September 25, 2022 at 2:02 am

Navratri fasting tips 2022: Managing blood sugar levels remains an everyday struggle for people with diabetes and when it comes to planning diabetes diet during Navratri fast, it is advised to be mindful of what you are eating and when you are eating during the day to prevent experiencing spike or drop in glucose levels. Stocking on low GI items is a good idea and there is no dearth of such vrat-friendly foods which will prevent sugar spikes. From singhara flour, buckwheat flour, roasted makhanas, peanuts, nuts and seeds, vegetables to fruits, there is a lot that diabetes can safely include in their Navratri diet. (Also read: Navratri 2022: Benefits of fasting)

"People with diabetes need to structure their meals and plan in advance to enjoy the full benefit of Navratri fasts. The main goal is to keep the blood sugar levels within normal range," says Dietician and Nutritionist Dr Poonam Duneja Founder of Nutrifybypoonam Diet & Wellness clinic.

Dr Duneja also offers the following fasting tips for people with diabetes.

- Keep your body hydrated and try to walk for 15 minutes after every meal.

- The navratri plate should have complex carbs and low-calorie drinks and meals distributed throughout the day. Do not eat heavy meals.

- Include low GI carbs like buckwheat roti in your meals. Add vegetables and also include a salad before all your meals to keep your post prandial sugar levels in check.

- Include good fats to reduce the glycemic load of the meals.

- Include low fat dairy proteins in buttermilk, yogurt, paneer to eliminate any sugar cravings and replenish your energy levels throughout the day.

- Mattha, vegetable raita, lassi, chaach, nuts and seeds can be added as an excellent protein source for people with diabetes during fasting.

- Including fruits and veggies result in better plasma carotenoids and Vitamin C levels, deliver antioxidants and phyto compounds. Try salads, fruit chaat, vegetable smoothies, vegetable soups and avoid readymade soups mix, fruit juices and sugary preparations.

"Researches show adding less than 30% calories from fat results in reducing glycated hemolobin levels (HBA1C levels). Include high fibre diet, less saturated fat and cholesterol less than 300 mg. Include omega-3 fatty acids (flax seeds, chia seeds, pumpkin seeds) to provide unsaturated heart healthy fats which results in elevated HDL levels, better serum lipids LDL and HbA1C," says Dr Duneja.

Follow more stories on Facebook &Twitter

More here:
Navratri fasting tips 2022: Dos and don'ts for people with diabetes during fasts - Hindustan Times

Posted in Diabetes | Comments Off on Navratri fasting tips 2022: Dos and don’ts for people with diabetes during fasts – Hindustan Times

Beware of these signs on your hands that indicate onset of diabetes – Times Now

Posted: September 25, 2022 at 2:02 am

Apart from the usual symptoms of the disease which include excessive thirst, weight loss, and numbness, diabetes also has some signs that appear on the hands and fingers, known as diabetic neuropathy

In the long run, most of the organs get affected by high blood sugar. Due to poor diet and lifestyle, not just older people but even youngsters fall prey to diabetes.

What is diabetic neuropathy?

Doctors say diabetic neuropathy is the extreme tingling in the hands that happens to more than 50 per cent of people who suffer from the disease.

The tingling and numbness can be severe in many people and can acutely even affect the working of fingers.

What are the symptoms?

Apart from the sensation in fingers, other symptoms of neuropathy include:

Weakness in hands

Paralysis on one side of the face

Pain behind the eye

Double vision

Focus problem

Disclaimer: Tips and suggestions mentioned in the article are for general information purposes only and should not be construed as professional medical advice. Always consult your doctor or a dietician before starting any fitness programme or making any changes to your diet.

Read the original here:
Beware of these signs on your hands that indicate onset of diabetes - Times Now

Posted in Diabetes | Comments Off on Beware of these signs on your hands that indicate onset of diabetes – Times Now

Why Winnie the Pooh Could Hold Key to Beating Diabetes – Newsweek

Posted: September 25, 2022 at 2:02 am

Winnie the Pooh could hold the key to beating diabetes, according to new research. Every year, bears gain an enormous amount of weight, then barely move for months.

A sugar-rich diet is the main trigger for the metabolic disorder in humans. It's caused by resistance to insulin, a hormone that controls glucose.

Bears can turn it on and off, almost like a switch, but scientists have found their secret: a particular set of hibernation proteins. Thousands of changes in gene expression were narrowed down to eight, specifically.

A Washington State University (WSU) team made the discovery by feeding honey, Pooh's favorite food, to hibernating bears.

"There seem to be eight proteins that are working either independently or together to modulate the insulin sensitivity and resistance that is seen in hibernating bears," said Professor Joanna Kelley, lead author of the study. "All of these eight proteins have human homologs. They are not unique to bears. The same genes are in humans, so that means maybe there is a direct opportunity for translation."

The scientists looked at changes in cell cultures exposed to blood serum drawn from grizzlies housed at the WSU Bear Centre.

Samples were collected during active and hibernating seasons - including one that was interrupted by being given water laced with honey.

Different cocktails highlighted the genetic alterations. It was serum from the mid-hibernation feeding period that helped most in identifying the important proteins.

"By feeding the bears just for two weeks during hibernation, it allowed us to control for other things like day length and temperature as well as food availability," Kelley said.

Bears usually get up and move a little during hibernation but do not eat, urinate or defecate.

Waking moments were used to offer them the treat. The extra sugar was also found to disrupt hibernation behavior - enabling the first study of its kind. When the serum was put onto a cell culture taken from regularly hibernating bears, they began to exhibit changes in gene activity similar to those from an active season.

Kelley and colleagues plan to investigate how the proteins work to reverse insulin resistance.

The findings may ultimately lead to the development of therapies that prevent, or even cure, diabetes.

"This is progress toward getting a better understanding of what is happening at the genetic level and identifying specific molecules that are controlling insulin resistance in bears," said co-first author Dr. Blair Perry of WSU.

Tools for understanding genetics are becoming more sophisticated. The researchers recently mapped the complete DNA of brown bears, of which grizzlies are a member.

The updated genome may help provide even better insights into bear genetics including how they manage hibernation.

Perry, who has also worked out the genetic makeup of snake venom, said: "There is inherent value to studying the diversity of life around us and all of these unique and strange adaptations that have arisen."

"By understanding the genomic basis of these adaptations, we gain a better understanding of what we share with other species, and what makes us unique as humans," Perry said.

The study in iScience is potentially priceless - for diabetics.

Produced in association with SWNS Talker.

This story was provided to Newsweek by Zenger News.

See the original post:
Why Winnie the Pooh Could Hold Key to Beating Diabetes - Newsweek

Posted in Diabetes | Comments Off on Why Winnie the Pooh Could Hold Key to Beating Diabetes – Newsweek

Managing diabetes could happen in the kitchen, Ohio State researchers find – 10TV

Posted: September 25, 2022 at 2:02 am

The key to managing diabetes could be as simple as what's cooking in your kitchen.

COLUMBUS, Ohio The key to controlling and managing diabetes could be as simple as what's cooking in your kitchen.

Researchers from The Ohio State University Wexner Medical Center and College of Medicine tested whether a cooking prescription that provides food, along with diabetes self-management education, would improve A1C levels.

Ohio State University Wexner Medical Center Certified Diabetes Care and Education Specialist Jennifer Shrodes said people diagnosed with diabetes should focus on portion sizes.

She said it's important that your plate is one-third protein, one-third nonstarchy vegetables and one-third carbohydrates.

Shrodes and her dietitian colleagues said that there are no so-called bad foods. Instead, they help participants understand how to track how frequently they eat food that might not be as full of healthy nutrients.

"This study really looked at what we're teaching people in the classroom and how do they take that information outside of the classroom and actually practice in their real-life," Shrodes said.

Researchers found that participants' blood sugar improved and many were back at baseline afterward. They said the key is to continue to practice what they've learned in diabetes education.

OSU chefs offer a free live-streamed 20-minute cooking demo twice a month on the second and fourth Tuesday at noon. Head over to theOSU Wexner Medical Cental website to register.

Read more:
Managing diabetes could happen in the kitchen, Ohio State researchers find - 10TV

Posted in Diabetes | Comments Off on Managing diabetes could happen in the kitchen, Ohio State researchers find – 10TV

More people with type 2 diabetes achieved blood sugar target with once-weekly insulin icodec compared with once-daily insulin degludec – GlobeNewswire

Posted: September 25, 2022 at 2:02 am

Data presented today show more participants achieved greater treatment satisfaction when switching to once-weekly insulin icodec in ONWARDS 2 trial

Bagsvrd, Denmark, Thursday 22 September 2022 Novo Nordisk today presented new data from the phase 3a ONWARDS 2 trial, demonstrating that 37% of adults with type 2 diabetes treated with once-weekly insulin icodec achieved an HbA1c <7.0%, without experiencing severe or clinically significant hypoglycaemia, compared with 27% of those treated with insulin degludec at 26 weeks1. These results were presented at the 58th European Association for the Study of Diabetes (EASD) Annual Meeting 20221.

Once-weekly insulin would be a remarkable step forward in insulin innovation, said Dr Athena Philis-Tsimikas, Scripps Whittier Diabetes Institute, California, USA, and principal investigator of ONWARDS 2. It could offer people with type 2 diabetes reduced treatment complexity and burden by reducing the number of basal insulin injections from 365 to 52 per year, without compromising management of blood sugar.

The trial achieved its primary endpoint of demonstrating non-inferiority in reducing HbA1c at week 26 with insulin icodec compared with insulin degludec2. From a mean baseline of 8.17% (icodec) and 8.10% (degludec), once-weekly insulin icodec achieved a superior reduction in estimated HbA1c of 0.93% compared with 0.71% for insulin degludec2.

People with diabetes in ONWARDS 2 reported significantly greater satisfaction in favour of once-weekly insulin icodec compared with insulin degludec at 26 weeks as assessed by the Diabetes Treatment Satisfaction Questionnaire (DTSQ) 1.

We are very pleased to see the promising results from the ONWARDS programme so far, said Martin Holst Lange, Executive Vice President Development, Novo Nordisk. The patient-reported outcomes data we see in ONWARDS 2 further strengthen our belief that insulin icodec has the potential to become the ideal insulin for people living with type 2 diabetes initiating insulin treatment.

The mean weekly insulin dose was 268 U/week for insulin icodec vs 244 U/week for insulin degludec1. The estimated mean change in body weight from baseline to week 26 was 1.40 kg for insulin icodec compared with 0.30 kg for insulin degludec1.

In the trial, once-weekly insulin icodec appeared to have a safe and well-tolerated profile. There was less than 1 hypoglycaemic event per patient-year exposed for insulin icodec and insulin degludec (0.73 events and 0.27 events per patient-year exposed, respectively, with no statistically significant difference between arms). As previously reported, no severe hypoglycaemia events were observed for people treated with insulin icodec1.

For more news and media materials from Novo Nordisk at EASD 2022, please visit: https://www.novonordisk.com/news-and-media/e-press-room.html?cid=nnref-1624925851

About insulin icodecInsulin icodec is a novel once-weekly basal insulin analogue designed to cover the basal insulin requirements for a full week with a single subcutaneous injection. Currently, the basal insulin products with the longest duration are injected once daily1. Insulin icodec is currently going through phase 3 clinical development.

About the ONWARDS clinical programme The ONWARDS clinical development programme for once-weekly insulin icodec comprises six phase 3a global clinical trials, including a trial with real-world elements, involving more than 4,000 adults with type 1 or type 2 diabetes2. Top-line data for the ONWARDS 1, 2, 3, 4 and 6 trials have now read out, all meeting their primary endpoints2-4.

About ONWARDS 2ONWARDS 2 trial is a phase 3a, 26-week efficacy and safety treat-to-target trial investigating once-weekly insulin icodec vs once-daily insulin degludec in 526 people with type 2 diabetes switching from daily insulin5. The primary endpoint was to assess the change in HbA1c at week 26 with insulin icodec compared with insulin degludec2.

About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 50,800 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.

Further information

_______________________

References1.Philis-Tsimikas A, Asong M, Franek E, et al. Once-weekly Insulin Icodec Demonstrated Better Glycaemic Control vs Once-daily Insulin Degludec in Basal Insulin-Treated Type 2 Diabetes. European Association for the Study of Diabetes (EASD) 58th Annual Meeting; 1923 September 2022; Stockholm, Sweden. 2.Novo Nordisk. Company announcement. Once-weekly insulin icodec demonstrates superior reduction in HbA1c vs insulin degludec in people with type 2 diabetes in ONWARDS 2 phase 3a trial. Available at: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=112839 Last accessed: September 2022. 3.Novo Nordisk. Company announcement. Novo Nordisk achieves primary objectives of ONWARDS 1 and 6 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin glargine U100 in ONWARDS 1. Available at: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=118349 Last accessed: September 2022. 4.Novo Nordisk. Company announcement. Novo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin degludec in ONWARDS 3. Available at: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=127304 Last accessed: September 2022. 5.ClinicalTrials.gov. A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin (ONWARDS 2). Available at: https://clinicaltrials.gov/ct2/show/NCT04770532 Last accessed: September 2022.

See the rest here:
More people with type 2 diabetes achieved blood sugar target with once-weekly insulin icodec compared with once-daily insulin degludec - GlobeNewswire

Posted in Diabetes | Comments Off on More people with type 2 diabetes achieved blood sugar target with once-weekly insulin icodec compared with once-daily insulin degludec – GlobeNewswire

West Virginia Diabetic Walk for Wellness held for the 5th year – WBOY.com

Posted: September 25, 2022 at 2:02 am

CLARKSBURG, W.Va. For the 5th year, the West Virginia Diabetic Walk For Wellness was hosted by Webster Insurance Agency at the Bridge Sports Complex in Bridgeport.

The event is meant to help promote diabetic wellness and raise awareness through education. It featured a display from United Hospital Center that showed the sugars in items we consume.

All donations from Saturdays event will be sent to the Diabetic Association for testing, equipment and anything to help to find a cure.

A lot of people dont realize the types of foods you need to eat, what you need to maintain your sugar. so, were hoping that this raises awareness and gets some information out to folks and realize this is a bad disease, said Joyce Hickman, agent with Webster Insurance Agency.

Hickman hopes that the event can grow larger year after year so it can promote wellness and raise more awareness for diabetes.

12 News own Don Graye said, Im a diabetic, I have been for a while. The association does so many good things, information, how to get contacts with people and so forth. So, its a worthwhile cause and diabetes is not a joke, its a serious matter.

If you would like to make a donation for the Diabetes Association, you can call 304-842-7311.

See original here:
West Virginia Diabetic Walk for Wellness held for the 5th year - WBOY.com

Posted in Diabetes | Comments Off on West Virginia Diabetic Walk for Wellness held for the 5th year – WBOY.com

CellResearch Corporation reports positive results of DFU trial – Labiotech.eu

Posted: September 25, 2022 at 2:01 am

CellResearch Corporation, a Singapore-based biopharma company says it has successfully closed the first phase I study for CorLiCyte, a stem cell therapy derived from umbilical cord lining stem cells, with research partners at the University of Colorado, Anschutz Medical Campus and ClinImmune Cell and Gene Therapy.

CorLiCyte is in development for the treatment of serious conditions, with a first target indication of treating diabetic foot ulcer (DFU). In the study protocol nine patients with chronic DFU were treated with CorLiCyte twice weekly for eight weeks. None of the patients participating in the study experienced any treatment-related adverse events and all subjects saw a reduction in wound size during the treatment period.

These results are encouraging and can be used to support further research with CorLiCyte in future studies, with the potential to address unmet medical needs in treatment of patients with chronic DFUs, said Cecilia Low-Wang, lead investigator at the University of Colorado, Anschutz Medical Campus.

Acoording to University of Michigan Health, a diabetic foot ulcer is an open sore or wound that occurs in approximately 15% of patients with diabetes, and is commonly located on the bottom of the foot. Of those who develop a foot ulcer, 6% will be hospitalized due to infection or other ulcer-related complications.

Diabetes is the leading cause of nontraumatic lower extremity amputations in the U.S., and approximately 14 to 24% of patients with diabetes who develop a foot ulcer have an amputation.

CorLiCyte is a live mesenchymal stem cell therapy derived from human umbilical cord lining stem cells, with a proprietary optimized expression of cytokines, growth and cellular factors for the treatment of a number of serious health conditions. In addition to DFU, CellResearch Corporation is pursuing a range of potential indications at pre-clinical stage such as osteoarthritis, venous leg ulcers, chronic inflammatory and autoimmune conditions.

CellResearch Corporation was founded in 2002 as a contract research provider focusing on skin cells. In 2004, the company made the discovery that the umbilical cord lining of mammals was an abundant source of both mesenchymal and epithelial stem cells. Today, the company owns this technology through a family of patents and holds the rights to commercialize this technology in most major markets globally.

CellResearch Corporation partner, Cordlife offers parents the opportunity to bank their childs umbilical cord tissue alongside their cord blood. Cordlife has what is believed to be the largest licensed bank of umbilical cord tissue globally. As cell therapies move into the clinic, Cordlife will have the ability to expand stem cells from a banked umbilical cord for autologous and donor-related uses.

More here:
CellResearch Corporation reports positive results of DFU trial - Labiotech.eu

Posted in Colorado Stem Cells | Comments Off on CellResearch Corporation reports positive results of DFU trial – Labiotech.eu

Page 221«..1020..220221222223..230240..»